

10/582856

AP20 Rec'd PCT/PTO 14 JUN 2006
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	James C. Barrow et al.	
Serial No.:	To Be Assigned	Case No.: 21592YP
US Nat'l Filing Date:	June 14, 2006	
Int'l Appl'n No.	PCT/US2004/042173	
Int'l Filing Date:	15 December 2004	
For:	PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

MAIL STOP PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT June 14, 2006
EXPRESS MAIL NO. EL989 585 305 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,
Alexandria, Virginia 22313-1450

MAILED BY
DATE

Gabriele B. Crowley
6/14/06

10/582856

Int'l Appl'n No.: PCT/GB2004/004985
Case No.: T1615YP

1AP20 Rec'd PCT/PTO 14 JUN 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference K on the accompanying PTO 1440 form was cited in the International Search Report for this application. A copy of the International Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By John C. Todaro
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: June 14, 2006

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN**Application Number**

To Be Assigned

Filing Date

June 14, 2006

First Named Inventor

James C. Barrow

Group Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket Number

21592YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	B		WO 2004/043916	PCT	Merck & Co., Inc.	05/27/2004
	C		WO 2004/062625	PCT	Merck & Co., Inc.	07/29/2004
	D		WO 2005/004802	PCT	Merck & Co., Inc.	01/20/2005
	E		WO 2005/004803	PCT	Merck & Co., Inc.	01/20/2005
	F		WO 2005/018545	PCT	Merck & Co., Inc.	03/03/2005
	G		WO 2005/032471	PCT	Merck & Co., Inc.	04/14/2005
	H		WO 2005/051914	PCT	Merck & Co., Inc.	06/09/2005
	I		WO 03/072535	PCT	Elan Pharmaceuticals, Inc.	09/04/2003
	J		EP 1 186 305	PCT	Schering Aktiengesellschaft	03/13/2002
	K		WO 02/02512	PCT	Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Co.	

**Examiner
Signature**

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

21592YP

COMPLETE IF KNOWN

To Be Assigned

June 14, 2006

James C. Barrow

To Be Assigned

To Be Assigned

[illegible][illegible]

Date Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

